Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for cancer therapy-induced thrombocytopenia
ChiCTR2500103356Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in Thrombocytopenia, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Recovery rate of platelet count. Planned start May 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2500103356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103356.